Advertisement

Topics

Hollis-Eden Pharmaceuticals, Inc. Company Profile

06:43 EST 21st November 2018 | BioPortfolio

Hollis-Eden Pharmaceuticals is a development-stage company with two product candidates in clinical trials: Apoptone® (HE3235), in the dose-escalation portion of a Phase I/II trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone® and Triolex® represent the lead candidates from Hollis-Eden's small molecule platform based on metabolites or synthetic analogs of endogenous steroid hormones. For more information on Hollis-Eden please visit www.holliseden.com.


News Articles [340 Associated News Articles listed on BioPortfolio]

Eden by Perrier-Jouët leva visitantes do centro de Tóquio para a Épernay subterrânea

TÓQUIO, 10 de maio de 2018 /PRNewswire/ -- Para acompanhar a Semana do Design de Tóquio, o Eden by Perrier-Jouët está fazendo sua terceira visita Read more...

Eden by Perrier-Jouët Takes Visitors From Downtown Tokyo to Underground Epernay

To view the Multimedia News Release, please click:   http://www.multivu.com/players/uk/8325851-eden-perrier-jouet-downtown-tokyo-epernay/ A pioneer of Art Nouveau, Perrier-Jouët is now using dig...

Eden Spine's low-profile plating system wins FDA clearance

The FDA has granted Eden Spine clearance to market its Sphynx plating system, a titanium, low-profile device designed to trea -More- 

Eden Prairie, MN Periodontist, Dr. Andres Sanchez, Trains With World-renowned Periodontists, Treats Gum and Bone Loss With Microsurgery

Dr. Andres Sanchez, a well-regarded periodontist in Eden Prairie, MN, has completed an intensive, three-day advanced periodontal regeneration microsurgery training to help patients who experience jaw-...

Respected Periodontist in Eden Prairie, MN, Dr. Andres Sanchez, Recertified by the American Board of Periodontology

Dr. Andres Sanchez, skilled periodontist in Eden Prairie, MN, has now been recertified by the American Board of Periodontology. Certification must be renewed to show clinicians have an ongoing commitm...

Offering brings in $5.4M for CHF Solutions

An offering of 2.2 million shares of common stock has been closed by Eden Prairie, Minn.-based CHF Solutions at $5.4 million. -More- 

Eden Research chairman hopes to oversee rise in revenue in coming year along with an increase in R&D activity

Lykele van der Broek said the AIM-listed company - that develops and supplies breakthrough biopesticide products - will, in short order, see crop protection, animal health and consumer products on the...

Eden Research rises as regulators approve subsidiary’s head-lice treatment for sale in Europe

TerpeneTech has been developing its head-lice treatment for the past three years and it will launch in the UK at the beginning of 2019

PubMed Articles [142 Associated PubMed Articles listed on BioPortfolio]

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

In the Garden of Eden: The Content of My Psychoses.

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Clinical Trials [236 Associated Clinical Trials listed on BioPortfolio]

Clinical Study of Gene-Eden-VIR/Novirin

This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.

Latarjet Versus Modified Eden-Hybinnette for Anterior Shoulder Dislocation

Randomized clinical trial, parallel 1:1, comparing Latarjet to Modified Eden-Hybinnett (iliac bone crest + capsular repair) for recurrent traumatic anterior glenohumeral dislocation.

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Companies [1353 Associated Companies listed on BioPortfolio]

Hollis-Eden Pharmaceuticals, Inc.

Hollis-Eden Pharmaceuticals is a development-stage company with two product candidates in clinical trials: Apoptone® (HE3235), in the dose-escalation portion of a Phase I/II trial of patients with la...

Hollis-Eden Pharmaceuticals

Hollis-Eden Pharmaceuticals is a development-stage pharmaceutical company, is engaged in the discovery, development and commercialization of products for the treatment of a number of targeted disease ...

Next-Generation Pharmacist

Civic Leader of the Year: Peter Crouch, RPh, CCP, Eden Drug, Eden, N.C.

Eden Biodesign Ltd.

Eden Biodesign is a globally-integrated biopharmaceutical company offering consultancy, biopharmaceutical design, process development and cGMP manufacturing services to leading bi...

Eden Biodesign

Eden Biodesign is an integrated biopharmaceutical development organisation that evolved out of Eden Biopharm, a successful international development and manufacturing consultancy. Eden Biodesign is th...

More Information about "Hollis-Eden Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Hollis-Eden Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Hollis-Eden Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Hollis-Eden Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Hollis-Eden Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Hollis-Eden Pharmaceuticals, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Obesity
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...


Corporate Database Quicklinks



Searches Linking to this Company Record